Yellow fever: An update

Lancet Infectious Diseases

Volumn 1, Issue 1, 2001, Pages 11-20

  Monath, Thomas P ^a,b  

^a Acambis   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

YELLOW FEVER VACCINE;

AEDES; AFRICA SOUTH OF THE SAHARA; ANIMAL; CLASSIFICATION; DISEASE CARRIER; DISEASE TRANSMISSION; GENETICS; GENOTYPE; HAPLORHINI; HUMAN; IMMUNOLOGY; INCIDENCE; REVIEW; RISK FACTOR; RODENT; SOUTH AMERICA; TRAVEL; VIROLOGY; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS; ZOONOSIS;

AEDES; AFRICA SOUTH OF THE SAHARA; ANIMALS; GENOTYPE; HAPLORHINI; HUMANS; INCIDENCE; INSECT VECTORS; RISK FACTORS; RODENTIA; SOUTH AMERICA; TRAVEL; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS; ZOONOSES;

EID: 0035436653     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(01)00016-0     Document Type: Review

References (36)

1. Zanotto P.M., de A., Gould E.A., Gao G.F., et al. Population dynamics of flaviviruses revealed by molecular phylogenies. Proc Natl Acad Sci USA. 93:1996;548-553.
2. Robertson S.E., Hull B.P., Tomori O., et al. Yellow fever. A decade of reemergence. JAMA. 27:1996;1157-1162.
3. Chambers T.J., Hahn C.S., Galler R., Rice C.M. Flavivirus genome organization, expression, and replication. Annu Rev Microbiol. 44:1990;649-660.
4. Digoutte J.-P., Cornet M., Deubel V., Downs W.G. Yellow fever. Porterfield J.S. Exotic viral infections. Kass handbook of infectious diseases. 1995;67-102 Chapman & Hall Medical, London.
5. Kerr J.A. The clinical aspects and diagnosis of yellow fever. Strode G.K. Yellow fever. 1951;629-640 McGraw-Hill, New York.
6. Oudart J.-L., Rey M. Protéinurie, protéinémie et transaminasémies dans 23 cas de fiévre jaune confirmée. Bull World Health Organ. 42:1970;95-101.
7. Santos F., Pereira Lima C., Paiva P., et al. Coagulaçao intravascular disseminada aguda na febre amarela: dosagem dos factores da coagulaçao. Brasilia Med. 9:1973;9-15.
8. Stevanson L.D. Pathological changes in the central nervous system in yellow fever. Arch Path. 27:1939;249-254.
9. Jones M.M., Wilson D.C. Clinical features of yellow fever casesat Vom Christian Hospital during the 1969 epidemic onthe Jos Plateau, Nigeria. Bull World Health Organ. 46:1972;63-65.
10. Tesh RB, Guzman H, Travassos da Rosa APA, et al. Experimental yellow fever virus infection in the golden hamster (Mesocricetus auratus). 1. Virologic, biochemical and immunologic studies. Am J Trop Med Hyg (in press).
11. Theiler M. The virus. Strode G.K. Yellow fever. 1951;46-136 McGraw Hill, New York.
12. Tigertt W.D., Berge T.O., Gochenour W.S., et al. Experimental yellow fever. Trans N Y Acad Sci. 22:1960;323-333.
13. Monath T.P., Brinker K.R., Chandler F.W., et al. Pathophysiologic correlations in a rhesus monkey model of yellow fever. Am J Trop Med Hyg. 30:1981;431-441.
14. Monath T.P., Ballinger M., Miller B.M., Salaun J. Detection of yellow fever viral RNA by nucleic acid hybridization and viral antigen by immunocytochemistry in fixed human liver tissues. Am J Trop Med Hyg. 40:1989;663-668.
15. Marianneau P., Steffan A.M., Royer C., et al. Differing infection patterns of dengue and yellow fever viruses in a human hepatoma cell line. J Infect Dis. 178:1998;1270-1278.
16. Deubel V., Huerre M., Cathomas G., et al. Molecular detection and characterization of yellow fever virus in blood and liver specimens of a non-vaccinated fatal human case. J Med Virol 1997. 53:1997;212-217.
17. Saluzzo J.-P., Monath T.P., Cornet M., et al. Comparison de différent techniques virologiques pour la détection du virus de fièvre jaune dans les prélêvements humains et des lots de moustiques. Intêrét d’une methode rapide de diagnostic par ELISA. Ann Virol (Inst Past). 136E:1985;115-129.
18. Monath T.P. Yellow fever: a medically neglected disease. Report on a seminar. Rev Infect Dis. 9:1987;165-175.
19. Monath T.P., Nasidi A. Should yellow fever vaccine be included in the expanded program of immunization in Africa? A cost-effectiveness analysis for Nigeria. Am J Trop Med Hyg. 48:1993;74-290.
20. Barrett A.D.T. Yellow fever vaccines. Biologicals. 25:1997;17-25.
21. Monath T.P. Yellow fever. Plotkin S., Orenstein W.A. Vaccines. 3rd edn :1999;815-880 WB Saunders, Philadelphia.
22. Hacker U.T., Jelinek T., Erhardt S., et al. In vivo synthesis of tumor necrosis factor-alpha in healthy humans after live yellow fever vaccination. J Infect Dis. 177:1998;774-778.
23. Reinhardt B., Jaspert R., Niedrig M., et al. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol. 56:1998;159-167.
24. Jennings A.D., Gibson C.A., Miller B.R., et al. Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis. J Infect Dis. 169:1994;512-518.
25. Kelso J.M., Mootrey G.T., Tsai T.F. Anaphylaxis from yellow fever vaccine. J Allergy Clin Immunol. 103:1999;698-701.
26. Martin M., Tsai T.F., Cropp B., et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet. 358:2001;98-104.
27. Vasconcelos P.F.C., Luna E.J., Galler R., et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet. 358:2001;91-97.
28. Chan R.C., Penney D.J., Little D., Carter I.W., Roberts J.A., Rawlinson W.D. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet. 358:2001;121-122.
29. Nasidi A., Monath T.P., Vandenberg J., et al. Yellow fever vaccination and pregnancy: a four-year prospective study. Trans R Soc Trop Med Hyg. 87:1993;337-339.
30. Robert E., Vial T., Schaefer C., Arnon J., Reuvers M. Exposure to yellow fever vaccine in early pregnancy. Vaccine. 17:1999;283-285.
31. Monath T.P., Giesberg J., Fierros E.G. Does restricted distribution limit access and coverage of yellow fever vaccine in the United States? Emerging Infect Dis. 4:1999;698-702.
32. Guirakhoo F., Weltzin R., Chambers T.J., et al. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol. 74:2000;5477-5485.
33. Monath T.P., Levenbook I., Soike K., et al. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J Virol. 74:2000;1742-1751.
34. McAllister A., Arbetman A.E., Mandl S., et al. Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases. J Virol. 74:2000;9197-9205.
35. Van der Stuyft P., Gianella A., Pirard M., et al. Urbanisation of yellow fever in Santa Crux, Bolivia. Lancet. 353:1999;1558-1562.
36. Miller B.R., Monath T.P., Tabachnick W.J., et al. Epidemic yellow fever caused by an incompetent mosquito vector. Trop Med Parasitol. 40:1989;396-399.